Clindamycin / Tretinoin Gel Suppliers & Bulk Manufacturers
Available Forms: Gel
Available Strengths: 1.0% + 0.025% w/w, 1.0% + 0.05% w/w
Reference Brands: Ziana (USA/LATAM), Veltin (USA), Clindate-T (India)
Category:
Derma Drugs
Clindamycin+Tretinoin is a combination of two medicines, used to treat acne, which appears as spots or pimples on your face, chest, or back. This medicine works by attacking the germs that cause them and rejuvenates sun-damaged skin.
Clindamycin / Tretinoin Gel is available in Gel
and strengths such as 1.0% + 0.025% w/w, 1.0% + 0.05% w/w.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Clindamycin / Tretinoin Gel is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Clindamycin / Tretinoin Gel can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Clindamycin phosphate 1.2% / tretinoin 0.025% gel is a topical combination therapy indicated for the treatment of acne vulgaris in patients aged 12 years and older. This once-daily formulation combines clindamycin, a lincosamide antibiotic that reduces acne-causing bacteria, with tretinoin, a retinoid that promotes skin cell turnover and prevents clogged pores. Together, they provide a dual mechanism of action that addresses both the microbial and follicular components of acne.
The efficacy and safety of this combination gel are well-established through extensive clinical studies. Three pivotal 12-week, randomized, vehicle-controlled trials involving over 1,800 subjects demonstrated significant improvement in inflammatory and non-inflammatory acne lesions. Additionally, an open-label 52-week study with 442 participants confirmed its long-term tolerability and skin safety. Pooled analyses from a total of 4,550 subjects further support the consistency of therapeutic outcomes.
Results from the Phase 3 studies in 845 subjects with mild to severe facial acne showed that the gel achieved clear or almost clear skin in a substantial proportion of patients, with many experiencing at least a 2-grade improvement in acne severity scores. Clindamycin phosphate 1.2% / tretinoin 0.025% gel is therefore a proven, effective, and safe once-daily option for managing acne vulgaris.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing